Estradiol Patch Cost in Oregon 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is the Cash Price for an Estradiol Patch in Oregon?

The average out-of-pocket cash price for a one-month supply of a brand estradiol transdermal patch at Oregon retail pharmacies in 2026 is approximately $35, compared with the manufacturer list price of $75. Generic estradiol patches are frequently available at major pharmacy chains for $20, $40 per month depending on dose and quantity. GoodRx and similar discount platforms sometimes reduce that further to $15, $25 at specific ZIP codes in Portland, Eugene, and Salem.

Prices shift based on dose. The 0.025 mg/day patch sits at the lower end of the cost range, while the 0.1 mg/day patch can run $5, $10 more per fill. A 2023 analysis published in JAMA Internal Medicine confirmed that generic transdermal estradiol remains one of the lowest-cost options in the hormone-therapy class, with broad availability at community pharmacies across the Pacific Northwest. [1]

Oregon has no state price-control law specific to hormonal medications, so prices are set by pharmacy benefit managers and individual pharmacy contracts. Calling ahead to compare prices at Fred Meyer Pharmacy, Walgreens, Rite Aid, and independent compounding pharmacies in your city is worth the two minutes it takes.

The FDA-approved estradiol transdermal patch label specifies that the patch should be applied to clean, dry, intact skin on the lower abdomen or buttock, rotated at each application. [2] That detail matters for efficacy, not just cost, because poor adherence from skin irritation is one of the top reasons patients switch products and incur new prescription costs.

According to the North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement, "transdermal estradiol is associated with a lower risk of venous thromboembolism and stroke than oral estrogen formulations." [3] That pharmacokinetic advantage means many Oregon clinicians now prefer the patch as a first-line route even when cost is not the primary concern.

For patients paying cash, asking for a 90-day supply at a mail-order pharmacy typically reduces the per-patch cost by 10, 15 percent compared with 30-day retail fills.

Does Oregon Medicaid (Oregon Health Plan) Cover the Estradiol Patch?

Oregon Medicaid, formally the Oregon Health Plan (OHP), covers estradiol transdermal patches for moderate-to-severe vasomotor symptoms of menopause, but a prior authorization (PA) is required. Without PA approval, the claim will deny at the pharmacy counter.

The PA criteria under OHP generally ask the prescribing clinician to document the diagnosis (ICD-10 N95.1 for menopausal vasomotor symptoms), confirm the absence of contraindications listed in the FDA label [2], and note that non-pharmacological measures were considered. Most OHP PA requests for estradiol patches are approved within 24 to 72 hours when documentation is complete. Preferred drug list (PDL) placement changes annually, so confirming the current preferred tier for estradiol transdermal at the OHP fee-for-service portal before writing the prescription avoids delays.

A 2019 Cochrane review of estrogen therapy for vasomotor symptoms (N=10 trials) found a mean reduction in hot-flash frequency of 75% with transdermal estradiol versus 50% with placebo, supporting the clinical necessity argument used in PA letters. [4] Oregon Medicaid managed care plans (Coordinated Care Organizations, or CCOs) may have slightly different PDLs; PacificSource, Trillium, and Health Share of Oregon each publish their own lists online.

Patients enrolled in OHP who receive PA approval typically pay $0, $3 per fill under the OHP copay schedule for preferred generics. Brand patches, if approved, may carry a higher tier copay but are still far below cash price.

The table below summarizes the OHP PA pathway for estradiol transdermal, which the HealthRX clinical team compiled by reviewing OHP published drug policies as of Q2 2025:

OHP Prior Authorization Pathway for Estradiol Transdermal

1. Prescriber submits PA form to OHP or CCO with ICD-10 N95.1 documentation.
2. Clinical pharmacist reviews contraindications per FDA label (active or recent arterial thromboembolic disease, undiagnosed abnormal uterine bleeding, estrogen-dependent neoplasia, liver dysfunction). [2]
3. OHP approves or denies within 72 hours; expedited review (24 hours) available for urgent cases.
4. Approved: patient fills at OHP-contracted pharmacy for $0, $3 copay.
5. Denied: prescriber may appeal or prescriber may pivot to 503A compounding if clinically appropriate.

Is Compounded Estradiol Transdermal Legal in Oregon?

Compounded estradiol transdermal preparations are legal in Oregon when prepared by a state-licensed 503A compounding pharmacy operating under Oregon Board of Pharmacy rules. A 503A pharmacy compounds on a per-patient, per-prescription basis and is not required to seek FDA approval for the individual preparation, though the active ingredient (estradiol USP) must meet pharmacopeial standards.

The FDA distinguishes 503A pharmacies (patient-specific compounding) from 503B outsourcing facilities (large-scale, FDA-registered). Oregon has multiple licensed 503A pharmacies that prepare estradiol transdermal gels, creams, and patches. The legality question that sometimes confuses patients relates to bulk compounding or copy-compounding of commercially available products. The FDA's guidance on compounding of drugs that are commercially available [5] states that pharmacies should not compound products that are essentially copies of FDA-approved drugs. Because commercial estradiol patches (Climara, Vivelle-Dot, Minivelle) are FDA-approved and widely available, a 503A pharmacy in Oregon must establish a clinical rationale (e.g., a patient-specific dose unavailable commercially, an allergy to a patch adhesive ingredient) to prepare a transdermal patch rather than refer to a commercial product. [5]

Compounded transdermal estradiol gels and creams face less regulatory friction because no FDA-approved topical gel in an identical dose and vehicle always matches every patient need. Many Oregon 503A pharmacies therefore offer customized transdermal gels or creams rather than patches, and the cost for these preparations ranges from $0 (if covered under a CCO formulary exception) to $25, $40 per month cash. Some patients report paying nothing when their prescriber files for CCO coverage under a medical exception.

The Oregon Board of Pharmacy compounding rules align with USP Chapter 795 for non-sterile preparations and require that the finished product meet identity, strength, quality, and purity standards before dispensing. [6] Patients should ask any compounding pharmacy for a certificate of analysis confirming the estradiol concentration in the finished preparation.

Which Insurance Plans Cover the Estradiol Patch in Oregon?

Most commercial insurance plans sold on Oregon's marketplace (OHP Connect / HealthCare.gov) cover generic estradiol transdermal on Tier 1 or Tier 2, meaning patient copays range from $0 to $45 per fill depending on plan design. The Affordable Care Act requires most plans to cover preventive services for women without cost-sharing, but estradiol for menopause is classified as a treatment rather than a USPSTF-graded preventive service, so the zero-cost-sharing mandate does not automatically apply. [7]

Oregon's insurance commissioner has not issued a menopause-specific coverage mandate beyond federal minimum requirements as of 2025. Patients with employer-sponsored plans should check their Summary of Benefits and Coverage (SBC) document for the "Prescription Drug Benefits" section. Generic estradiol patches appear on virtually every formulary in Oregon because the drug is off-patent and inexpensive for insurers to cover.

Medicare Part D covers estradiol transdermal; the specific tier and copay vary by plan. In 2026, the Medicare Part D out-of-pocket cap is $2,000 annually under the Inflation Reduction Act provisions, which limits catastrophic spending for patients with complex medication needs. [8] Medicare Advantage plans in Oregon (Providence Health Plan, Regence BlueCross BlueShield, Kaiser Permanente) each publish formularies searchable at medicare.gov.

Regence BlueCross BlueShield of Oregon and Providence Health Plan generally place generic estradiol transdermal on Tier 1 with a $0, $10 copay for a 30-day supply as of their 2025 published formularies. PacificSource Community Solutions, operating as an OHP CCO, lists estradiol transdermal on its preferred drug list.

How Do Climara, Vivelle-Dot, and Minivelle Savings Cards Work in Oregon?

Brand manufacturer savings cards reduce the out-of-pocket cost for commercially insured patients to as low as $0, $25 per month. The operative word is "commercially insured." Patients covered by Medicare, Medicaid (OHP), or any other federal or state government-funded program are not eligible to use manufacturer copay cards under federal anti-kickback statute guidelines. [9]

Bayer (Climara) has historically offered a savings card program through its website that allows eligible patients to pay no more than $25 for a 30-day supply at participating pharmacies. Therapeutics MD and other brands have run similar offers for Vivelle-Dot. Patients activate the card online or via phone, then present it at the pharmacy alongside their insurance card. The card acts as secondary insurance, covering the gap between what the plan pays and the patient copay, up to a plan-year maximum (typically $1,500, $2,400 per year).

Oregon pharmacies participate in these programs at standard rates. No Oregon-specific restriction prevents commercially insured residents from using manufacturer copay assistance as of 2026. Because savings card terms change annually, patients should verify eligibility and benefit maximums directly at the manufacturer's website before relying on the card for budgeting purposes.

For patients who are uninsured or ineligible for savings cards (e.g., OHP enrollees), the most cost-effective option is usually a generic estradiol transdermal patch purchased with a GoodRx or RxSaver coupon at a high-volume pharmacy such as Costco or Walmart in Oregon. In a 2022 JAMA study examining pharmacy pricing transparency, Costco and Mark Cuban's Cost Plus Drugs consistently offered the lowest cash prices for generic hormonal medications. [10]

Can I Get an Estradiol Patch Prescription via Telehealth in Oregon?

Telehealth prescribing of estradiol transdermal is legal in Oregon. Oregon Revised Statutes and Oregon Medical Board rules permit prescribing via synchronous video visit when the clinician establishes a valid patient-provider relationship, performs an appropriate clinical evaluation, and documents a diagnosis consistent with the prescription. [11]

The Ryan Haight Online Pharmacy Consumer Protection Act applies to controlled substances, not estradiol, so no in-person visit requirement exists under federal law for hormone therapy. Oregon state law similarly does not mandate a physical examination before prescribing estradiol transdermally, provided that the telehealth encounter meets the standard of care.

A 2021 study in Menopause (the journal of NAMS) found that telehealth delivery of menopause care was rated equally satisfactory to in-person care by 89% of patients, with no difference in prescribing accuracy for hormone therapy (N=342). [12] That evidence base supports what many Oregon patients are already doing: scheduling a 20-minute video visit with a licensed Oregon clinician, receiving an estradiol patch prescription electronically, and filling it at a local or mail-order pharmacy the same day.

Patients should confirm that the telehealth clinician holds an active Oregon medical or advanced practice license. Prescriptions for estradiol generated by a licensed out-of-state provider who has not registered with the Oregon Medical Board do not meet Oregon pharmacy dispensing requirements.

What Does the Clinical Evidence Say About Estradiol Patch Safety and Efficacy?

The estradiol transdermal patch is FDA-approved for moderate-to-severe vasomotor symptoms, moderate-to-severe symptoms of vulvar and vaginal atrophy, and prevention of postmenopausal osteoporosis. [2] The safety profile of transdermal versus oral estrogen was substantially clarified by the Women's Health Initiative (WHI) Estrogen-Alone trial (N=10,739), published in JAMA in 2004, which studied conjugated equine estrogen 0.625 mg orally daily in hysterectomized women. The WHI authors noted a non-significant reduction in coronary heart disease risk with estrogen alone (hazard ratio 0.91 to 95% CI 0.75, 1.12) but a statistically significant increase in stroke risk (HR 1.39 to 95% CI 1.10, 1.77). [13]

The transdermal route bypasses hepatic first-pass metabolism and produces lower hepatic synthesis of clotting factors, which is why subsequent observational data and the ESTHER study (N=881, published in Circulation 2007) found no significant increase in venous thromboembolism risk with transdermal estradiol versus a nearly fourfold increase with oral estradiol. [14] This pharmacokinetic distinction is the primary reason the NAMS 2022 Position Statement specifically calls out transdermal delivery as the preferred route for patients with elevated VTE risk. [3]

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) demonstrated that low-dose transdermal estradiol (0.045 mg/day patch) and oral conjugated equine estrogen did not differ significantly from placebo in progression of carotid intima-media thickness over 4 years, supporting the hypothesis that timing relative to menopause onset matters more than route for cardiovascular outcomes. [15]

Endometrial safety requires co-administration of a progestogen for women with an intact uterus. The NAMS 2022 statement specifies that "estrogen without progestogen is contraindicated in women with a uterus." [3] Micronized progesterone 200 mg orally for 12 days per cycle or continuous progesterone 100 mg daily are the most common regimens paired with an estradiol patch in Oregon clinical practice.

What Is the Cheapest Way to Get an Estradiol Patch in Oregon in 2026?

The lowest-cost pathways, ranked by typical monthly out-of-pocket cost for Oregon residents in 2026, are:

1. Oregon Health Plan (OHP) with PA approval: $0, $3 per month for preferred generic estradiol transdermal.
2. Commercially insured with Tier 1 generic placement: $0, $10 per month copay at Regence or Providence plans.
3. Cash price with GoodRx/RxSaver coupon at Costco or Walmart Oregon: $15, $25 per month.
4. 503A compounding pharmacy (clinically justified formulation, covered under CCO exception): $0, $30 per month.
5. Average Oregon retail cash price without coupon: ~$35 per month.
6. Brand patch (Climara, Vivelle-Dot, Minivelle) with manufacturer savings card (commercially insured only): $0, $25 per month.
7. Brand patch at list price, uninsured, no coupon: $75 per month.

Combining a coupon with a 90-day mail-order supply at a pharmacy such as Optum Rx or Express Scripts typically produces the lowest unit cost for uninsured patients who do not qualify for OHP.

A 2020 study in the Annals of Internal Medicine found that simply presenting a GoodRx coupon reduced estrogen prescription costs by a median of 43% at U.S. retail pharmacies. [16] Oregon pharmacies are not required to accept third-party discount cards, but the vast majority do.

Patients who cannot afford their estradiol patch should ask their prescribing clinician about patient assistance programs (PAPs) offered by Bayer for Climara. The Bayer Patient Assistance Program provides free medication to uninsured or underinsured patients who meet income criteria, generally below 200 to 400% of the federal poverty level. Applications are submitted through the prescriber's office.